# Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.

> **NCT03168022** · PHASE1 · COMPLETED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Healthy Adults

## Interventions

- **DRUG:** Treatment A
- **DRUG:** Treatment B

## Key facts

- **NCT ID:** NCT03168022
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-16
- **Primary completion:** 2016-01-26
- **Final completion:** 2016-01-26
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168022, "Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03168022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*